BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul

BACE1 or β-secretase, an aspartyl protease enzyme was found majorly in neurons and its appearance and activity were found to be elevated in the brains of AD patients. A flavonoid compound, myricetin and a carbazole alkaloid compound, mahanimbine were tested for their BACE1 inhibitory activity using...

Full description

Saved in:

Bibliographic Details
Main Author:	Hasnul, Izzati
Format:	Thesis
Language:	English
Published:	2012
Subjects:	Therapeutics Psychotherapy Alzheimer's disease
Online Access:	https://ir.uitm.edu.my/id/eprint/66680/1/66680.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-uitm-ir.66680
record_format	uketd_dc
spelling	my-uitm-ir.666802022-09-14T01:45:12Z BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul 2012 Hasnul, Izzati Therapeutics. Psychotherapy Alzheimer's disease BACE1 or β-secretase, an aspartyl protease enzyme was found majorly in neurons and its appearance and activity were found to be elevated in the brains of AD patients. A flavonoid compound, myricetin and a carbazole alkaloid compound, mahanimbine were tested for their BACE1 inhibitory activity using the BACE1 fluorescence resonance energy transfer (FRET) assay kit with compounds concentration ranging from 0.1μg/ml to 1000μg/ml. Both compounds, at its highest concentration (1000μg/ml), was found to exhibit more than 90% inhibition of BACE1 in the preliminary screening. Mahanimbine was found to be the more active compound against BACE1 activity with IC50 value of 5.0μg/ml, when compared to myricetin (IC50 value = 17.0μg/ml). These results indicate that at the highest concentration mahanimbine was able to inhibit BACE1 activity more than myricetin, and the IC50 values indicate that at 50% inhibition mahanimbine was able to inhibit BACE1 activity at a lower concentration than myricetin. This study shows that both myricetin and mahanimbine may have potential as therapeutic or preventive agents for AD via inhibitory activity of BACE1. However, further studies and more extensive studies are warranted on both compounds to improve their potential as neuroprotective agents and for their inhibitory activity against BACE1 in order to develop anti-Alzheimer or anti-dementia therapy. 2012 Thesis https://ir.uitm.edu.my/id/eprint/66680/ https://ir.uitm.edu.my/id/eprint/66680/1/66680.pdf text en public degree Universiti Teknologi MARA (UiTM) Faculty of Pharmacy Mohd Noor Hazalin, Nurul Aqmar Ramasamy, Kalavathy Mani, Vasudevan
institution	Universiti Teknologi MARA
collection	UiTM Institutional Repository
language	English
advisor	Mohd Noor Hazalin, Nurul Aqmar Ramasamy, Kalavathy Mani, Vasudevan
topic	Therapeutics Psychotherapy Alzheimer's disease
spellingShingle	Therapeutics Psychotherapy Alzheimer's disease Hasnul, Izzati BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul
description	BACE1 or β-secretase, an aspartyl protease enzyme was found majorly in neurons and its appearance and activity were found to be elevated in the brains of AD patients. A flavonoid compound, myricetin and a carbazole alkaloid compound, mahanimbine were tested for their BACE1 inhibitory activity using the BACE1 fluorescence resonance energy transfer (FRET) assay kit with compounds concentration ranging from 0.1μg/ml to 1000μg/ml. Both compounds, at its highest concentration (1000μg/ml), was found to exhibit more than 90% inhibition of BACE1 in the preliminary screening. Mahanimbine was found to be the more active compound against BACE1 activity with IC50 value of 5.0μg/ml, when compared to myricetin (IC50 value = 17.0μg/ml). These results indicate that at the highest concentration mahanimbine was able to inhibit BACE1 activity more than myricetin, and the IC50 values indicate that at 50% inhibition mahanimbine was able to inhibit BACE1 activity at a lower concentration than myricetin. This study shows that both myricetin and mahanimbine may have potential as therapeutic or preventive agents for AD via inhibitory activity of BACE1. However, further studies and more extensive studies are warranted on both compounds to improve their potential as neuroprotective agents and for their inhibitory activity against BACE1 in order to develop anti-Alzheimer or anti-dementia therapy.
format	Thesis
qualification_level	Bachelor degree
author	Hasnul, Izzati
author_facet	Hasnul, Izzati
author_sort	Hasnul, Izzati
title	BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul
title_short	BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul
title_full	BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul
title_fullStr	BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul
title_full_unstemmed	BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul
title_sort	bace1 inhibitory activity of myricetin and mahanimbine / izzati hasnul
granting_institution	Universiti Teknologi MARA (UiTM)
granting_department	Faculty of Pharmacy
publishDate	2012
url	https://ir.uitm.edu.my/id/eprint/66680/1/66680.pdf
_version_	1783735631035236352

BACE1 inhibitory activity of myricetin and mahanimbine / Izzati Hasnul

Similar Items